A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Andexanet alfa (Primary) ; Apixaban; Edoxaban; Enoxaparin sodium; Rivaroxaban
- Indications Haemorrhage
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Portola Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 06 Sep 2017 Planned End Date changed from 31 Aug 2017 to 30 Sep 2017.